Confirming a belief of many of us, new research has found that hormone therapy (endocrine therapy or ADT) is associated with a very large increased risk of developing various major heart problems. This research also tells us that some therapy options have a higher risk profile than others. At Europe's biggest cancer congress, ECCO 15 [...]
Clinical trials are the lifeblood of new drug and treatment development. Trials allow us to learn what developing drugs and treatment are both safe and effective. Many drug developers complain about their inability to attract enough volunteers to reach a sample size that will allow them to draw statistically valid conclusions. Everyday there are trials [...]
Advanced prostate cancer will progress and most of us will face a time when Androgen Deprivation Therapy (ADT) stops working. Most men on ADT take a LHRH agonist, which turns off the production of testosterone (i.e. Lupron) along with a non-steroidal anti-androgen (i.e. Casodex) that prevents the small amount of testosterone that continues to be [...]
The use of Docetaxel (chemotherapy) extends survival time in men with castration-resistant prostate cancer (CRPC). Many researchers believe that platinum compounds, particularly Carboplatin, when added to docetaxel (taxane-based chemotherapy) can further extend survival times. A study at the Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Investigated the efficacy [...]
Docetaxel (Taxotere), or chemotherapy, will as all other treatments for advanced prostate cancer stop working. Many of us will progress quickly to this stage and eventually face a situation where there are no longer any approved treatments available to control our prostate cancer. If you are lucky enough to have an oncologist who is creative [...]